BeiGene Ltd. (BGNE)

133.01
0.73 0.55
NASDAQ : Health Technology
Prev Close 132.28
Open 132.28
Day Low/High 131.66 / 133.88
52 Wk Low/High 105.19 / 164.99
Volume 306.16K
Avg Volume 308.00K
Exchange NASDAQ
Shares Outstanding 60.35M
Market Cap 7.67B
EPS -12.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Celgene Says Juno, Impact Deals Won't Be Its Last

Celgene Says Juno, Impact Deals Won't Be Its Last

The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

TheStreet Quant Rating: D (Sell)